Contains madecassic acid, centella asiatica extract, asiaticoside, and asiatic acid to soothe sensitive skin and moisturize skin
The evidence tier that is fully published and verifiable is Phase 2
Once-daily subcutaneous injection for 812 weeks, optionally extended to ~16 weeks
It is essential to discuss your full health history, current medications, and recent lab results during your Klinic evaluation to ensure this treatment is safe for you
We intend for the survey to be completed in time for the survey results to be used to inform policy making beginning with the CY 2027 OPPS/ASC proposed rule
By focusing on stringent quality control and transparent manufacturing, the Polaris peptide line has set a new benchmark for excellence